IRIDEX (IRIX) Stock Price, News & Analysis

Company Overview

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration. In addition to laser systems, IRIDEX offers a range of laser probes, fibers and accessories that enable physicians to tailor treatments to individual patient needs and optimize clinical outcomes.

Since its founding in 1983, IRIDEX has expanded its global footprint, serving ophthalmic practices, surgical centers and hospitals in over 50 countries. Headquartered in Mountain View, California, the company maintains regional operations and distribution partnerships across North America, Europe, Asia-Pacific and Latin America. IRIDEX continues to invest in research and development to enhance its proprietary technologies and support new applications in retinal and glaucoma care.

IRIDEX’s management team is led by Thomas T. Weppelmann Jr., President and Chief Executive Officer, who has guided the company through multiple product launches and market expansions. Under his leadership, IRIDEX has built a reputation for delivering reliable, precision-engineered laser systems and fostering long-term collaborations with clinical partners. The company remains committed to advancing ophthalmic therapy through ongoing innovation and partnerships with academic institutions and key opinion leaders.

Key Stats

• Today's Range: $0.69 to $0.72
• 50-Day Range: $0.70 to $1.17
• 52-Week Range: $0.69 to $1.65
• Volume: 73,878 shs
• Average Volume: 105,512 shs
• Market Capitalization: $12.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

IRIDEX Stock Analysis - MarketRank™

IRIDEX scored higher than 32% of companies evaluated by MarketBeat, and ranked 736th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

IRIDEX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

IRIDEX has a consensus price target of $3.00, representing about 328.6% upside from its current price of $0.70.

Amount of Analyst Coverage

IRIDEX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IRIDEX is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IRIDEX is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.24% of the float of IRIDEX has been sold short.

Short Interest Ratio / Days to Cover

IRIDEX has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IRIDEX has recently increased by 29.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IRIDEX does not currently pay a dividend.

Dividend Growth

IRIDEX does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IRIDEX insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.60% of the stock of IRIDEX is held by insiders.

Percentage Held by Institutions

20.10% of the stock of IRIDEX is held by institutions.

Company Calendar

• Last Earnings: 8/18/2026
• Today: 9/06/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:IRIX
• CIK: 1006045
• Web: www.iridex.com
• Phone: (650) 940-4700
• Fax: 650-940-4710
• Employees: 120
• Year Founded: 1989

Price Target and Rating

• Average Price Target for IRIDEX: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +328.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.44 million
• Net Margins: -6.88%
• Pretax Margin: -6.58%
• Return on Equity: N/A
• Return on Assets: -12.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.82
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $52.67 million
• Price / Sales: 0.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.13) per share
• Price / Book: -5.38

Miscellaneous

• Outstanding Shares: 17,570,000
• Free Float: 16,054,000
• Market Cap: $12.30 million
• Optionable: Optionable
• Beta: 0.62